New Safety Information regarding the antidiuretic drug desmopressin (DDAVP® Spray and DDAVP® Rhinyle Solution)
2008-08-03
Ferring Pharmaceuticals, in collaboration with Health Canada, the Canadian counterpart to the Saudi Food and Drug Authority (SFDA), inform health care professionals that all intranasal formulations of Desmopressin including Desmopressin Acetate Nasal(DDAVP) Spray & Desmopressin acetate Rhinyle Solution (DDAVP) are no longer indicated for the treatment of Primary Nocturnal Enuresis (PNE) due to an increased risk of hyponatremia with the intranasal formulations.